Alibaba to pay US $600M to settle allegations it allowed illegal drug and equipment sales
Chinese e-commerce giant Alibaba will pay $600 million to the U.S. government to settle allegations that its platforms facilitated the sale and import of illegal pharmaceuticals, controlled substances, regulated chemicals, and pill-making equipment into the United States.

Briefing Summary
AI-generatedChinese e-commerce giant Alibaba will pay $600 million to the U.S. government to settle allegations that its platforms facilitated the sale and import of illegal pharmaceuticals, controlled substances, regulated chemicals, and pill-making equipment into the United States. The U.S. government alleged that Alibaba's U.S.-based payment processor, AUS Merchant Services, failed to prevent merchants from selling these illegal products through Alibaba.com and AliExpress.com. Alibaba acknowledged in an agreement with the Justice Department that between January 2016 and December 2024, it failed to stop approximately 80,000 product sales involving unlawful imports. The settlement, a non-prosecution agreement, resolves concerns raised by Alibaba employees about inadequate compliance controls. Law enforcement agencies conducted numerous undercover purchases as part of the investigation.
Article analysis
Model · rule-basedKey claims
5 extractedA non-prosecution agreement was crafted between Alibaba and the Justice Department.
Law enforcement conducted over 40 undercover purchases of illegal pharmaceuticals and equipment.
Alibaba employees raised concerns that the company’s compliance controls were inadequate and failed to prevent the sale of illegal products.
Alibaba acknowledges failing to stop roughly 80,000 product sales involving unlawful imports between January 2016 and December 2024.
Alibaba will pay $600 million to resolve a dispute with the U.S. government over allegations of selling illegal pharmaceuticals and controlled substances.